Clinicopathologic Consequences Following Discontinuation of Rifaximin in Patients with Sickle Cell Disease

Authors

Seah H. Lim, New York Medical CollegeFollow
Dibyendu Dutta

Journal Title

American Journal of Hematology

First Page

151

Last Page

153

Document Type

Article

Publication Date

6-2020

Department

Medicine

Recommended Citation

Lim, S. H., & Dutta, D. (2020). Clinicopathologic Consequences Following Discontinuation of Rifaximin in Patients with Sickle Cell Disease. American Journal of Hematology, 95 (6), 151-153. https://doi.org/10.1002/ajh.25798